-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
On December 8, 2022, Z33 Bio Inc. An Entity Controlled By Zura Entered Into The License, Development And Commercialization Agreement With Eli Lilly And Company
On December 8, 2022, Z33 Bio Inc. An Entity Controlled By Zura Entered Into The License, Development And Commercialization Agreement With Eli Lilly And Company
As previously announced on June 16, 2022, JATT Acquisition Corp, a Cayman Islands exempted company ("JATT" or the "SPAC") entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time) (the "Business Combination Agreement" or "BCA"), among JATT, JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT ("Merger Sub"), JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT ("Merger Sub 2"), Zura Bio Holdings Ltd, a Cayman Islands exempted company (the "Holdco") (to become a party before Closing, as described below) and Zura Bio Limited, a limited company incorporated under the laws of England and Wales (the "Company" or "Zura").
Effective on December 8, 2022, Z33 Bio Inc. ("Z33"), an entity controlled by Zura entered into the License, Development and Commercialization Agreement (the "License Agreement") with Eli Lilly and Company ("Lilly"), pursuant to which Lilly granted a license to Z33 regarding certain intellectual property rights for a certain compound relating to IL-33 to develop, manufacture and commercialize such compound, subject to the terms and conditions set forth therein.
Equity Grant Agreement
Concurrently with the execution of the License Agreement, on December 8, 2022, as partial consideration for Lilly entering into the License Agreement with Z33, JATT and Lilly entered into that certain Equity Grant Agreement, pursuant to which JATT agreed to issue and grant to Lilly 550,000 Class A ordinary shares of JATT (the "Shares") in a private placement transaction. The Equity Grant Agreement also contains customary representations, warranties, and covenants of each of JATT and Lilly. The closing under the Equity Grant Agreement will occur contemporaneously on the closing of the transactions contemplated in the Business Combination Agreement.
Other than the benefit of the License Agreement with Z33, JATT will not receive any consideration from Lilly for issuance of the Shares to Lilly.
Pursuant to the Equity Grant Agreement, the Company agreed to register the Shares being issued to Lilly under an Amended and Restated Registration Rights Agreement (the "Registration Rights Agreement") with respect to the Shares in the form attached as Exhibit A to the Equity Grant Agreement. Additionally, Lilly agreed to enter into a lock-up with respect to the Shares under the Lock-up Agreement attached as Exhibit B to the Equity Grant Agreement.
The Registration Rights Agreement will govern the registration of the Shares for resale and be effective as of the Closing, and includes certain customary demand registration rights requiring the company to file a registration statement with respect to the Shares within 30 days after the Closing, and "piggy-back" registration rights with respect to the Shares held by Lilly.
As previously announced on June 16, 2022, JATT Acquisition Corp, a Cayman Islands exempted company ("JATT" or the "SPAC") entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time) (the "Business Combination Agreement" or "BCA"), among JATT, JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT ("Merger Sub"), JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT ("Merger Sub 2"), Zura Bio Holdings Ltd, a Cayman Islands exempted company (the "Holdco") (to become a party before Closing, as described below) and Zura Bio Limited, a limited company incorporated under the laws of England and Wales (the "Company" or "Zura").
正如之前在 2022 年 6 月 16 日宣布的,JATT 收購公司,開曼群島豁免公司(「JATT」或「SPAC」)訂立業務合併協議(因為它可能會被修訂,補充或以其他方式修改)(「業務合併協議」或「BCA」),在開曼群島獲得免稅和全資子公司(JATT 合併)的全資子公司(「業務合併協議」或「BCA」)JATT 合併子 2,開曼群島豁免公司和 JATT 的全資附屬公司(「合併子 2」),開曼群島豁免了祖拉生物控股有限公司公司(「控股公司」)(在關閉前成為一方,如下所述)和 Zura Bio Limited(根據英格蘭和威爾斯法律註冊成立的有限公司(「該公司」或「Zura」)。
Effective on December 8, 2022, Z33 Bio Inc. ("Z33"), an entity controlled by Zura entered into the License, Development and Commercialization Agreement (the "License Agreement") with Eli Lilly and Company ("Lilly"), pursuant to which Lilly granted a license to Z33 regarding certain intellectual property rights for a certain compound relating to IL-33 to develop, manufacture and commercialize such compound, subject to the terms and conditions set forth therein.
由 Zura 控制的實體 Z33 Bio Inc.(「Z33」)於 2022 年 12 月 8 日生效,根據莉莉與禮來公司(「禮來公司」)簽訂許可,開發和商業化協議(「許可協議」),根據禮來向 Z33 授予與 IL-33 相關的某些化合物的某些知識產權的許可,以開發和商業化的條件,以制定該化合物和商業化條件在其中之外。
Equity Grant Agreement
股權授予協議
Concurrently with the execution of the License Agreement, on December 8, 2022, as partial consideration for Lilly entering into the License Agreement with Z33, JATT and Lilly entered into that certain Equity Grant Agreement, pursuant to which JATT agreed to issue and grant to Lilly 550,000 Class A ordinary shares of JATT (the "Shares") in a private placement transaction. The Equity Grant Agreement also contains customary representations, warranties, and covenants of each of JATT and Lilly. The closing under the Equity Grant Agreement will occur contemporaneously on the closing of the transactions contemplated in the Business Combination Agreement.
隨著許可協議的執行,在 2022 年 12 月 8 日,作為莉莉與 Z33 簽訂許可協議的部分考慮,JATT 和禮來達成了某些股權授予協議,根據該協議,JATT 同意在私人配售交易中向 Lilly 550,000 股 A 類普通股(「股份」)發行並授予 JATT 的 A 類普通股(「股份」)。股權授予協議還包含 JATT 和禮來公司的習慣陳述,保證和契約。股權授予協議下的關閉將同時發生在業務合併協議中計劃的交易的關閉。
Other than the benefit of the License Agreement with Z33, JATT will not receive any consideration from Lilly for issuance of the Shares to Lilly.
除了與 Z33 簽訂的許可協議的好處外,JATT 將不會從禮來獲得向禮來公司發行股份的任何考慮。
Pursuant to the Equity Grant Agreement, the Company agreed to register the Shares being issued to Lilly under an Amended and Restated Registration Rights Agreement (the "Registration Rights Agreement") with respect to the Shares in the form attached as Exhibit A to the Equity Grant Agreement. Additionally, Lilly agreed to enter into a lock-up with respect to the Shares under the Lock-up Agreement attached as Exhibit B to the Equity Grant Agreement.
根據股權授予協議,本公司同意根據經修訂和重述的登記權協議(「登記權協議」),以隨附於股權授予協議附件 A 的表格對股份進行登記。此外,莉莉同意根據股權授予協議附件 B 附件的鎖定協議,就股份進行鎖定。
The Registration Rights Agreement will govern the registration of the Shares for resale and be effective as of the Closing, and includes certain customary demand registration rights requiring the company to file a registration statement with respect to the Shares within 30 days after the Closing, and "piggy-back" registration rights with respect to the Shares held by Lilly.
登記權協議將管理股份的登記以進行轉售,並於截止日期起生效,並包括若干慣常的要求登記權,要求公司在收市後 30 天內就股份提交登記聲明,以及就禮來所持有的股份提交「補充」登記權。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧